EBS Stock Analysis: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$5.11
0.03 (0.51%)
▲
5d:
+13.46%
30d:
-29.67%
90d:
-39.58%
HOLD
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EBS trades at premium valuation expecting 11.2% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: EBS trades at premium valuation expecting 11.2% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.23
Based on -9.1% avg growth
INTRINSIC VALUE TODAY
$1.39
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $5.11, which is considered slightly low relative to its 30-day fair value range of $5.01 to $7.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 18.1) compared to its historical average (13.2). At these levels, the market is pricing in 11.2% annual earnings growth.
Technical Outlook: Technically, EBS is in a strong downtrend. The price is approaching resistance at $5.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EBS scores 91/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.00 (+116.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EBS is in a strong downtrend. The price is approaching resistance at $5.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EBS scores 91/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.00 (+116.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.01 -
$7.79
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
93.8%
Protect Your Profits
Holding EBS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (91/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 116.5% below Wall St target ($11.00)
- BULLISH: Expecting earnings turnaround to 11.2% growth with 66.3% revenue growth
- CAUTION: Bottoming setup, but lagging the sector by 29% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$5.01 -
$7.79
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.36
Resistance Level
$5.11
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.14
Wall Street Target
$11.00
(+116.5%)
Revenue Growth (YoY)
66.3%
Earnings Growth (YoY)
-93.8%
Profit Margin
-23.0%
Valuation Premium vs History
+11.2% premium
PE vs Historical
18.1 vs 13.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.2%
(market-implied from PE analysis)
1-Year Target
$5.65
(+11%)
2-Year Target
$6.28
(+24%)
3-Year Target
$6.99
(+38%)
3-Yr Target (if PE normalizes)
(PE: 18→13)
PE COMPRESSION
$5.08
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: -22.2%)
$4.10
(+-19%)
Base:
(SPY PE: 18.1, Growth: -22.2%)
$3.70
(-27%)
Bear:
(PE: 13.2, Growth: -22.2%)
$2.69
(-47%)
Share & Embed Analysis
Last updated: August 24, 2026 12:55 PM ET
Data refreshes hourly during market hours. Next update: 1:55 PM
Data refreshes hourly during market hours. Next update: 1:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
